Background Observational studies have suggested a higher risk of thrombotic events in
patients with coronavirus disease 2019 (COVID-19). Moreover, elevated D-dimer levels …

Background COVID-19 is associated with a prothrombotic state leading to adverse clinical
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Background: Coronavirus disease 2019 (COVID-19) is associated with elevated rates of
major and fatal thrombotic events, postulated to be the result of a hypercoagulable state …

Background SARS-CoV-2 infection has noted derangements in coagulation markers along
with significant thrombotic complications. Post-mortem examinations show severe …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Background COVID-19 is associated with a prothrombotic state. Current guidelines
recommend prophylactic anticoagulation upon hospitalization. Methods COVID-PREVENT …

Background Previous studies demonstrate a reduced risk of thrombosis and mortality with
anticoagulant treatment in patients with COVID-19 than in those without anticoagulation …

Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with
increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has …

Background COVID-19 infection is associated with D-dimer elevations, high rates of
thrombus formation, and poor clinical outcomes. We sought to determine if empiric …